Titan Pharmaceuticals Inc. | Ownership
Companies that own Titan Pharmaceuticals Inc.
Renaissance Technologies LLC
648,400
3.06%
46,700
0%
06/30/2018
The Vanguard Group, Inc.
376,277
1.78%
-1,151
0%
06/30/2018
Geode Capital Management LLC
95,909
0.45%
8,560
0%
06/30/2018
Northern Trust Investments, Inc.
52,639
0.25%
0
0%
06/30/2018
Winning Points Advisors LLC
50,000
0.24%
0
0.07%
02/28/2018
Millennium Management LLC
43,670
0.21%
-46,840
0%
06/30/2018
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)
36,883
0.17%
19
0%
06/30/2018
The California Public Employees Retirement System
28,073
0.13%
0
0%
06/30/2018
Wedbush Securities, Inc. (Investment Management)
20,192
0.1%
20,192
0%
06/30/2018
The Bank of New York Mellon Corp. (Investment Management)
12,828
0.06%
0
0%
06/30/2018
| Address |
400 Oyster Point Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.titanpharm.com |
| Updated |
07/08/2019 |
| Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform. |
